Axia Pharmaceutical Recalls AscorbiX Injection Due to Sterility Concerns
Axia Pharmaceutical is recalling AscorbiX (Buffered C) Injection because the product lacks assurance of sterility. The recall covers specific lots distributed in the U.S., Puerto Rico, Barbados, and the Dominican Republic.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe rating under the rubric. The hazard involves a lack of assurance of sterility in an injectable product, posing a significant risk of infection.
Plain-English summary
Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical is recalling AscorbiX (Buffered C) Injection, a 30 mL multi-dose vial containing 500 mg/mL of ascorbic acid. The product is intended for intravenous, intramuscular, and subcutaneous use and is prescription-only. The recall is being conducted because the product lacks assurance of sterility.
The affected lots are 07112019+52635 (expiration date 1/17/2020) and 09092019+52890 (expiration date 3/17/2020). These products were distributed nationwide in the United States, as well as in Puerto Rico, Barbados, and the Dominican Republic.
Healthcare providers and patients should stop using the affected lots of AscorbiX Injection. Consumers should contact their healthcare provider for guidance on alternative treatments or further instructions regarding the recalled product.
The recalled product
- Product
- AscorbiX (Buffered C) Injection, Ascorbix (30ML) 500MG/ML Injectable, For IV, IM, SC Use, Refrigerate, 30 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0226-3
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 07112019+52635
- Exp 1/17/2020
- 09092019+52890
- Exp 3/17/2020
Distribution
Part of a larger recall action
This product is one of 63 recalled by Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 63 products in this recall →Related recalls
Same manufacturer · Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
See all →- Severe
- SevereAxia Pharmaceutical Recalls Selenium Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- Severe
- SevereAxia Pharmaceutical Recalls Hydroxyprogesterone Caproate Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- SevereAxia Pharmaceutical Recalls Alprostadil Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29